Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 6/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3326854 | 0.91 | KMT2A (0.40) | CNR1TRPV4TRPM8SMN1; SMN2ALDH1A1 | |
| SCHEMBL3327642 | 0.89 | ALDH1A1 (0.45) | PTGDR2SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL3324726 | 0.87 | RORC (0.34) | TRPV4PTGDR2RORC | |
| SCHEMBL3329390 | 0.84 | CNR1 (0.38) | CNR1TRPV4TRPM8PTGDR2PKM | |
| SCHEMBL27780327 | 0.84 | CNR1 (0.37) | CNR1TRPV4PKMSMN1; SMN2ALDH1A1 | |
| SCHEMBL4431234 | 0.83 | RORC (0.36) | PTGDR2ALDH1A1RORC | |
| SCHEMBL3332006 | 0.80 | MAPK1 (0.43) | SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL4636743 | 0.80 | PTGES (0.38) | CNR1PTGDR2PKMALDH1A1 | |
| SCHEMBL3327671 | 0.78 | MAPT (0.33) | TRPV4SMN1; SMN2RORC | |
| SCHEMBL4636233 | 0.77 | PTGDR2 (0.41) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137300-A1 | Indolizine Acetic Acid Derivatives as CRTH2 Antagonists | ARGENTA ORAL THERAPEUTICS LIMITED (GB) | 2010-06-03 | — | — | US | claimed |
| US-20100137300-A1 | Indolizine Acetic Acid Derivatives as CRTH2 Antagonists | ARGENTA ORAL THERAPEUTICS LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| US-20100137300-A1 | Indolizine Acetic Acid Derivatives as CRTH2 Antagonists | ARGENTA ORAL THERAPEUTICS LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| US-20100137300-A1 | Indolizine Acetic Acid Derivatives as CRTH2 Antagonists | ARGENTA ORAL THERAPEUTICS LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| US-20100137300-A1 | Indolizine Acetic Acid Derivatives as CRTH2 Antagonists | ARGENTA ORAL THERAPEUTICS LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| EP-2136804-A1 | INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | Argenta Oral Therapeutics Limited (GB) | 2009-12-30 | — | — | EP | disclosed |
| EP-2136804-A1 | INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | Argenta Oral Therapeutics Limited (GB) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008113965-A1 | INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008113965-A1 | INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008113965-A1 | INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137300-A1 | Indolizine Acetic Acid Derivatives as CRTH2 Antagonists | HRH1, HRH4, HRH2 | CNR1 296/4885TRPV4 629/4885TRPM8 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.